Skip to main content
. 2017 Apr 6;20(1):21472. doi: 10.7448/IAS.20.1.21472

Table 2.

Participants characteristics at enrolment by site location. PrEP Brasil-2015

Participant’s characteristics Total RJ SP Chi-Square
Overall 4501 180 (40.0%) 270 (60%) <0.01
Socio-demographics2        
Age       0.02
18–24 years 113 58 (32.2%) 55 (20.4%)  
25–35 years 214 76 (42.2%) 138 (51.1%)  
≥35 years 123 46 (25.6%) 77 (28.5%)  
Colour/Race       <0.01
White 243 60 (33.5%) 183 (68.8%)  
Black 57 41 (22.9%) 16 (6.0%)  
Mixed Race 145 78 (43.6%) 67 (25.2%)  
Schooling       <0.01
<12 years 115 81 (45.0%) 34 (12.6%)  
≥12 years 335 99 (55.0%) 236 (87.4%)  
Gender       <0.01
Male 425 161 (89.4%) 265 (97.8%)  
Trans women 25 19 (10.6%) 6 (2.2%)  
Housing situation       <0.01
Rent or own housing 289 98 (55.7%) 191 (71.5%)  
Other (live with friends/family, live in public housing) 154 78 (44.3%) 76 (28.5%)  
Steady partner       0.51
Yes 254 105 (58.3%) 149 (55.2%)  
No 196 75 (41.7%) 121 (44.8%)  
Sexual behaviour in last 3 months        
Had sex with client       0.63
Yes 27 12 (6.7%) 15 (5.6%)  
No 423 168 (93.3%) 255 (94.4%)  
Unprotected receptive anal intercourse     0.28
Yes 201 86 (47.8%) 115 (42.6%)  
No 249 94 (52.2%) 155 (57.4%)  
Sex with HIV-positive partners       0.11
Yes 223 80 (46.5%) 143 (54.4%)  
No 212 92 (53.5%) 120 (45.6%)  
Median Number of male partners (IQR) 3 (1–10) 3 (1–10) 4 (1–10) 0.22 3
Sexual role with male partners     0.29
Insertive 112 41 (23.0%) 71 (26.6%)  
Receptive 49 16 (9.0%) 33 (12.4%)  
Both 284 121 (68.0%) 163 (61.0%)  
Substance use and mental health        
Binge drinking       0.91
Yes 266 107 (59.4%) 159 (58.9%)  
No 184 73 (40.6%) 111 (41.1%)  
Any illicit drug use in past 3 months       0.05
Yes 134 44 (24.7%) 90 (33.5%)  
No 313 134 (75.3%) 179 (66.5%)  
Marijuana       0.19
Yes 128 45 (25.0%) 83 (30.7%)  
No 322 135 (75.0%) 187 (69.3%)  
Stimulants (cocaine, crack, amphetamines)     0.01
Yes 62 16 (8.9%) 46 (17.0%)  
No 388 164 (91.1%) 224 (83.0%)  
Hallucinogens (solvents, LSD, ketamine)     0.45
Yes 38 13 (7.2%) 25 (9.3%)  
No 412 167 (92.8%) 245 (90.7%)  
Tranquilizers       0.44
Yes 30 10 (5.6%) 20 (7.4%)  
No 420 170 (94.4%) 250 (92.6%)  
Erectile dysfunction drugs       0.10
Yes 51 15 (8.3%) 36 (13.3%)  
No 399 165 (91.7%) 234 (86.7%)  
Depression PHQ score       0.62
PHQ-2 score ≥ 3 27 12 (6.7%) 15 (5.6%)  
PHQ-2 score < 3 422 167 (93.3%) 255 (94.4%)  
STD diagnosis       0.87
Yes 89 35 (19.7%) 54 (20.3%)  
No 355 143 (80.3%) 212 (79.7%)  
Active/recent syphilis2       0.94
Yes 43 17 (9.6%) 26 (9.8%)  
No 401 161 (90.4%) 240 (90.2%)  
Chlamydia       0.05
Yes 36 9 (5.1%) 27 (10.2%)  
No 408 169 (94.9%) 239 (89.8%)  
Gonorrhoea       0.33
Yes 22 11 (6.2%) 11 (4.1%)  
No 422 167 (93.8%) 255 (95.9%)  
Risk perception      
Number of HIV tests in 12 months prior inclusion     <0.01
0 76 52 (32.7%) 24 (10.4%)  
1–3 235 91 (57.2%) 144 (62.3%)  
>3 79 16 (10.1%) 63 (27.3%)  
PEP in 12 months prior inclusion       0.34
Yes 91 33 (20.9%) 58 (25.0%)  
No 299 125 (79.1%) 174 (75.0%)  
Any GI symptoms2       0.01
Yes 178 40 (24.1%) 138 (53.5%)  
No 246 126 (75.9%) 120 (46.5%)  

TGW= Transgender women, STD =Sexually transmitted diseases, RJ= Rio de Janeiro, SP= São Paulo, PHQ= Patient Health Questionnaire, GI= Gastrointestinal. PEP = Post exposure prophylaxis. 1There was missing information for: Housing situation (n = 7), Sexual role with male (n = 5), Any illicit drug use in last 3 months (n = 3), STDs (n = 6), Number of HIV tests in 12 months prior inclusion (n = 60), PEP in 12 months prior inclusion (n = 60). 5 individuals who reported yellow/indigenous are not included in this table. 2Socio-demogrphics, except “Housing situation”, were assessed at pre-screening visit. Syphilis was assessed at screening visit and GI symptoms, at week 4. All other variables are from enrolment visit. 3Kruskal-Wallis Test.